Dominique Joyal
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Dominique Joyal has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Ernesto L. Schiffrin
Department of Medicine, McGill University
2 shared publications Mark J. Eisenberg
Department of Internal Medicine, Jewish General Hospital, McGill University, Montreal, Canada; Division of Cardiology, Jewish General Hospital, McGill University, Montreal, Canada
2 shared publicationsAvi Shimony
1 shared publicationDavid Zhang
Department of Internal Medicine, Jewish General Hospital, McGill University, Montreal, Canada
1 shared publicationJonathan Afilalo
Department of Internal Medicine, Jewish General Hospital, McGill University, Montreal, Canada; Division of Cardiology, Jewish General Hospital, McGill University, Montreal, Canada
1 shared publication- Kristian B. Filion
Department of Medicine McGill University Montreal Quebec Canada
1 shared publication
Latest Publications
- 11 October 2014
- Published by Springer Nature in Current Treatment Options in Cardiovascular Medicine
- Vol. 16 (12) , 1-12
Renal Denervation Therapy for Resistant Hypertension
Hypertension is common and leads to significant cardiovascular morbidity and mortality. Some patients are unable to achieve target blood pressures despite multiple antihypertensive medications; these patients are labeled as having resistant hypertension. To palliate the lack of pharmacologic options, recent technological advances led to the development of an interventional procedure to treat hypertension, namely renal sympathetic denervation. This percutaneous procedure involves the ablation of the afferent and efferent nerves surrounding the renal arteries. Many studies that were primarily observational in nature had very promising results. Systolic blood pressure reductions in the order of 25–30 mm Hg were observed in a series of unblinded studies, leading to the approval and widespread use of this technology across Europe, Australia, and Canada. However, a recent rigorous single blinded sham-controlled clinical trial failed to meet its efficacy endpoints. There are several postulated reasons for the conflicting results, which are discussed in this manuscript. These recent findings make us reflect on the need for rigorous clinical trials prior to the early approval and clinical adoption of novel technologies. At the moment, renal denervation remains an investigational procedure. Several trials are underway using different technologies, which, upon completion, will clarify the proper role of renal denervation for the treatment of patients with resistant hypertension.
- 11 October 2014
- Published by Springer Nature in Current Treatment Options in Cardiovascular Medicine
- Vol. 16 (12) , 1-12
Renal Denervation Therapy for Resistant Hypertension
Hypertension is common and leads to significant cardiovascular morbidity and mortality. Some patients are unable to achieve target blood pressures despite multiple antihypertensive medications; these patients are labeled as having resistant hypertension. To palliate the lack of pharmacologic options, recent technological advances led to the development of an interventional procedure to treat hypertension, namely renal sympathetic denervation. This percutaneous procedure involves the ablation of the afferent and efferent nerves surrounding the renal arteries. Many studies that were primarily observational in nature had very promising results. Systolic blood pressure reductions in the order of 25–30 mm Hg were observed in a series of unblinded studies, leading to the approval and widespread use of this technology across Europe, Australia, and Canada. However, a recent rigorous single blinded sham-controlled clinical trial failed to meet its efficacy endpoints. There are several postulated reasons for the conflicting results, which are discussed in this manuscript. These recent findings make us reflect on the need for rigorous clinical trials prior to the early approval and clinical adoption of novel technologies. At the moment, renal denervation remains an investigational procedure. Several trials are underway using different technologies, which, upon completion, will clarify the proper role of renal denervation for the treatment of patients with resistant hypertension.
- 1 March 2012
- Published by Elsevier in The American Journal of Cardiology
- Vol. 109 (6) , 813-818
Meta-Analysis of Ten Trials on the Effectiveness of the Radial Versus the Femoral Approach in Primary Percutaneous Coronary Intervention
- 1 March 2012
- Published by Elsevier in The American Journal of Cardiology
- Vol. 109 (6) , 813-818
Meta-Analysis of Ten Trials on the Effectiveness of the Radial Versus the Femoral Approach in Primary Percutaneous Coronary Intervention